Back to top
more

Eli Lilly (LLY)

(Real Time Quote from BATS)

$889.47 USD

889.47
763,877

+4.99 (0.56%)

Updated Oct 2, 2024 12:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 17% (44 out of 252)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Merck (MRK) Halts Late Stage Alzheimer Study; Shares Slip

Merck & Co., Inc. (MRK) announced that it is discontinuing a late-stage study evaluating its pipeline candidate, verubecestat for the treatment of mild-to-moderate Alzheimer's disease due to lack of efficacy.

    Lilly's Olumiant Gets Marketing Authorization in Europe

    Eli Lilly and Company (LLY) along with its partner Incyte Corporation (INCY) announced that the European Commission has granted marketing authorization to once-daily baricitinib in Europe.

      Drug Stocks Earnings Slated for Feb 14: INCY, PRTA & More

      The year 2017 seems to have started on a positive note for investors in the U.S. Approximately 71.6% of the companies (or 358 members) in the S&P 500 Index have reported results so far.

        Amgen's Secondary Hyperparathyroidism Drug Approved in U.S.

        Amgen Inc. (AMGN) announced that the FDA has approved Parsabiv (etelcalcetide) for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis.

          GW Pharma (GWPH) Posts Narrower-than-Expected Loss in Q1

          GW Pharmaceuticals plc (GWPH) reported first-quarter fiscal 2017 loss of 77 cents per share, much narrower than both the Zacks Consensus Estimate of a loss of $1.35 and the year-ago figure of 82 cents.

            ARIAD Files for EU Approval of Lung Cancer Drug Brigatinib

            ARIAD Pharmaceuticals, Inc. (ARIA) announced the submission of a Marketing Authorisation Application (MAA) for its experimental ALK inhibitor, brigatinib, with the European Medicines Agency (EMA).

              Auris (EARS) Expands Pipeline with Intranasal Betahistine

              Auris (EARS) announced that it has strengthened its pipeline by the addition of AM-125 as the third clinical-stage program, which allowed it to expand into the field of vestibular disorders.

                Sweta Killa headshot

                Q4 Earnings Faring Well for Pharma ETFs

                Despite the fact that the industry primes posted mixed results, the stocks witnessed smooth trading following their results.

                  Drug Stocks Reporting Earnings on Feb 7: GILD, MNK & More

                  Earnings growth turned positive in the last quarter and things are surely looking up as we stand in the middle of the earnings season.

                    Bristol-Myers' Injectable Opdivo Gets FDA Approval for mUC

                    Bristol-Myers Squibb Company (BMY) announced that the FDA has approved an injectable form of immuno-oncology drug Opdivo

                      The Zacks Analyst Blog Highlights: Eli Lilly, Aetna, Automatic Data Processing, Dollar General and Sprint

                      The Zacks Analyst Blog Highlights: Eli Lilly, Aetna, Automatic Data Processing, Dollar General and Sprint

                        AstraZeneca (AZN) Beats on Q4 Earnings but Misses on Sales

                        AstraZeneca PLC (AZN) reported fourth-quarter 2016 core earnings of $1.21 per American Depositary Share, which comfortably beat the Zacks Consensus Estimate of 51 cents. Core earnings also rose 9% year over year.

                          Merck (MRK) Tops Q4 Earnings; Pharmaceutical Sales Down

                          Merck & Co., Inc. (MRK) reported fourth-quarter 2016 earnings of 89 cents per share, which beat the Zacks Consensus Estimate of 88 cents by a penny.

                            Sheraz Mian headshot

                            Q4 Scorecard and Analyst Reports for Eli Lilly, ADP & Aetna

                            Today's Research Daily features new research reports on 16 major stocks and a real-time update on the Q4 earnings season.

                              Drug Stocks to Report Q4 Earnings on Feb 2: MRK & AMGN

                              How will these two drug stocks, MRK & AMGN, which are both scheduled to report Q4 results on Feb 2, fare this earnings season?

                                Arpita Dutt headshot

                                Drug Stocks Rally on Trump Meet with Pharma Bigwigs

                                Pharma and biotech stocks were up as President Trump discussed a speedier drug approval process, lower regulations and corporate tax reforms.

                                  Ryan McQueeney headshot

                                  Biotech Stocks Gain on Latest Trump Drug Price Statements

                                  President Trump continues to double down on his campaign promises, and his latest statements regarding drug prices and regulation have sent biotech stocks higher on Tuesday.

                                    Eli Lilly (LLY) Misses on Q4 Earnings, Beats on Revenues

                                    Eli Lilly (LLY) reported fourth quarter earnings of 95 cents on revenues of $5.76 billion.

                                      Incyte and Calithera Enter into Deal for Oncology Candidate

                                      Incyte Corporation (INCY) and Calithera Biosciences, Inc. (CALA) entered into a global collaboration and license agreement for research, development and commercialization of Calithera's CB-1158 in hematology and oncology.

                                        Lilly (LLY) Q4 Earnings Miss, Revenues Beat

                                        Eli Lilly (LLY) reported fourth quarter earnings of 95 cents on revenues of $5.76 billion.

                                          Is a Surprise Coming for Eli Lilly (LLY) This Earnings Season?

                                          Eli Lilly (LLY) could be an interesting stock for investors ahead of earnings, as it has a positive ESP and a favorable Zacks Rank.

                                            Arpita Dutt headshot

                                            Key Takeaways from AbbVie's Q4 Call: Humira and the Pipeline

                                            2017 will be a year of significant R&D investment for AbbVie (ABBV) as well as several late-stage readouts which will give an insight into the company's long term growth prospects.

                                              Drug Stocks Reporting Q4 Earnings on Jan 31: LLY and PFE

                                              Two pharma giants - Pfizer and Lilly - are set to report fourth-quarter results on Jan 31. Let's see how things are shaping up for this quarter.

                                                Merck (MRK): Stock to Gain on Likely Earnings Beat in Q4?

                                                We expect pharma heavyweight Merck & Co., Inc. (MRK) to beat expectations when it reports fourth-quarter 2016 and full-year earnings results on Feb 2.

                                                  Will Amgen (AMGN) Keep the Earnings Streak Alive in Q4?

                                                  We expect biotech major Amgen Inc. (AMGN) to beat expectations when it reports fourth-quarter 2016 and full-year results on Feb 2.